Regencell Bioscience Holdings Limited (RGC)
| Market Cap | 3.12B -62.0% |
| Revenue (ttm) | n/a |
| Net Income | -11.70M |
| EPS | -0.02 |
| Shares Out | 495.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,407 |
| Open | 6.83 |
| Previous Close | 6.71 |
| Day's Range | 6.21 - 6.97 |
| 52-Week Range | 4.51 - 69.00 |
| Beta | 1.71 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 17, 2026 |
About RGC
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Full Company ProfileFinancial Performance
Financial StatementsNews
Regencell Bioscience rises 11.7%
Regencell Bioscience (RGC) is up 11.7%, or 95c to $9.06.
Regencell Bioscience rises 8.4%
Regencell Bioscience (RGC) is up 8.4%, or 69c to $8.88.
Regencell Bioscience rises 9.0%
Regencell Bioscience (RGC) is up 9.0%, or 64c to $7.77.
Regencell Bioscience rises 9.1%
Regencell Bioscience (RGC) is up 9.1%, or 65c to $7.76.
Regencell Bioscience Holdings Annual report: Q4 2026
Regencell Bioscience Holdings has published its Q4 2026 annual report on October 7, 2026.
Regencell Bioscience rises 25.2%
Regencell Bioscience (RGC) is up 25.2%, or $1.50 to $7.45.
Regencell Bioscience rises 29.6%
Regencell Bioscience (RGC) is up 29.6%, or $1.80 to $7.89.
Regencell Bioscience falls -16.0%
Regencell Bioscience (RGC) is down -16.0%, or -$1.20 to $6.29.
Regencell Bioscience falls -11.5%
Regencell Bioscience (RGC) is down -11.5%, or -86c to $6.63.
Regencell Bioscience falls -13.6%
Regencell Bioscience (RGC) is down -13.6%, or -$1.16 to $7.40.
Regencell Bioscience falls -14.3%
Regencell Bioscience (RGC) is down -14.3%, or -$1.58 to $9.50.
Relevant Gold Announces Results of Annual and Special General Meeting and Welcomes New Board Member
VANCOUVER, BC / ACCESS Newswire / June 18, 2026 / Relevant Gold Corp. (TSXV:RGC)(OTCQB:RGCCF) (the "Company" or "Relevant Gold") is pleased to announce the voting results from its Annual and Special G...
Relevant Gold South Pass VTEM Survey Defines Multi-Kilometre Structural Corridors with High Priority Drill Targets
Airborne VTEM and magnetics survey identifies 44+ EM anomalies, including 15 high-priority targets, several coincident with known gold-bearing structures, surface geochemistry and 2024 drilling VANCOU...
Regencell Bioscience falls -14.7%
Regencell Bioscience (RGC) is down -14.7%, or -$2.46 to $14.27.
RGC Investors Have Rights – If You Lost Money Investing in Regencell Bioscience Holdings Limited Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings ...
Regencell Bioscience falls -10.7%
Regencell Bioscience (RGC) is down -10.7%, or -$3.31 to $27.52.
Regencell Bioscience falls -7.1%
Regencell Bioscience (RGC) is down -7.1%, or -$2.19 to $28.64.
Regencell Bioscience falls -9.5%
Regencell Bioscience (RGC) is down -9.5%, or -$3.22 to $30.50.
Regencell Bioscience rises 49.5%
Regencell Bioscience (RGC) is up 49.5%, or $12.59 to $38.02.
Regencell Bioscience rises 23.9%
Regencell Bioscience (RGC) is up 23.9%, or $6.07 to $31.50.
Regencell Bioscience files to sell ordinary shares, no amount given
06:16 EDT Regencell Bioscience (RGC) files to sell ordinary shares, no amount given
Regencell Bioscience falls -8.7%
Regencell Bioscience (RGC) is down -8.7%, or -$2.37 to $25.00.
Regencell Bioscience rises 15.4%
Regencell Bioscience (RGC) is up 15.4%, or $3.53 to $26.50.
Regencell Bioscience rises 26.7%
Regencell Bioscience (RGC) is up 26.7%, or $6.14 to $29.11.
This $14 Billion Meme Stock Says It Is Developing a Herbal Remedy for Autism
The Nasdaq-listed company has recurring losses and no revenue.